tiprankstipranks
Advertisement
Advertisement
Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target
PremiumRatingsIntellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target
16d ago
Intellia Therapeutics presents additional results from Phase 3 HAELO trial
Premium
The Fly
Intellia Therapeutics presents additional results from Phase 3 HAELO trial
17d ago
Intellia Shareholders Back Board, Executive Pay and Auditor
Premium
Company Announcements
Intellia Shareholders Back Board, Executive Pay and Auditor
21d ago
Intellia Therapeutics price target lowered to $19 from $20 at BofA
PremiumThe FlyIntellia Therapeutics price target lowered to $19 from $20 at BofA
2M ago
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
Premium
The Fly
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
2M ago
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
Premium
The Fly
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
2M ago
Unusually active option classes on open April 29th
PremiumThe FlyUnusually active option classes on open April 29th
2M ago
Intellia Therapeutics 16.7M share Secondary priced at $10.75
Premium
The Fly
Intellia Therapeutics 16.7M share Secondary priced at $10.75
2M ago
Cathie Wood Makes $14M Bet on Alphabet Stock Ahead of Today’s Q1 Earnings, Buys the Dip in CRWV and Trims Bullish Stake
Premium
Market News
Cathie Wood Makes $14M Bet on Alphabet Stock Ahead of Today’s Q1 Earnings, Buys the Dip in CRWV and Trims Bullish Stake
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100